$15.330
-0.428 (-2.79%)At close
GENB News
GENB Events
Generate Biomedicines Stock Falls 16.7% to $16.97
Generate Biomedicines is down -16.7%, or -$3.41 to $16.97.
Generate Biomedicines Stock Falls 11% to $18.13
Generate Biomedicines is down -11.0%, or -$2.25 to $18.13.
Generate Biomedicines Stock Rises 17.7% to $20.86
Generate Biomedicines is up 17.7%, or $3.14 to $20.86.
Generate Biomedicines Stock Falls 9.5% to $14.22
Generate Biomedicines is down -9.5%, or -$1.50 to $14.22.
Generate Biomedicines Advances Multiple Clinical Trials
"We saw strong progress in the first quarter across our clinical pipeline, next generation of therapeutic programs, and advancing our platform," said Mike Nally, chief executive officer of Generate Biomedicines, Inc. "We are advancing GB-0895 in Phase 3 for severe asthma and Phase 1b for COPD. In oncology, we expect to progress two clinical trials this year with GB-4362, an MMAE neutralizer, and GB-5267, a MUC16 CAR T developed with Roswell Park. Together, these programs reflect the breadth of our clinical portfolio across therapeutic areas, modalities, and both wholly owned and partnered programs."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.